Compare EPOW & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPOW | KYNB |
|---|---|---|
| Founded | 2014 | 1993 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.9M | 31.9M |
| IPO Year | 2019 | N/A |
| Metric | EPOW | KYNB |
|---|---|---|
| Price | $0.84 | $6.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 162.5K | 26.8K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $6.32 |
| 52 Week High | $1.86 | $9.58 |
| Indicator | EPOW | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 48.27 | 47.25 |
| Support Level | $0.74 | $6.56 |
| Resistance Level | $1.05 | $7.58 |
| Average True Range (ATR) | 0.10 | 0.34 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 28.38 | 56.14 |
E Power Inc, through its subsidiaries, is engaged in the manufacturing and sale of graphite anode material for lithium-ion batteries. The company operates a plant in Guizhou Province, China, powered by electricity from renewable sources, which contributes to the plant's low production costs and reduced environmental impact in the production of graphite anode materials. Additionally, it also operates a knowledge sharing platform business.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.